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Abstract
Background: Red cell distribution width (RDW) in acute heart failure (AHF) is accepted as a prognos-
tic indicator with unclear pathophysiological ties. The aim of this study was to evaluate the prognostic 
value of RDW in AHF patients in relation to clinical and echocardiographic data. 
Methods: 170 patients with AHF  were retrospectively studied. All patients had laboratory testing and 
an echocardiogram performed within 24 h of admission to the Cardiology Department. 
Results: During the mean 193 ± 111 days of follow-up, 33 patients died. More advanced age, high 
RDW and low peak early diastolic velocity of the lateral mitral annulus (MVe’) were independent pre-
dictors of all-cause mortality with hazard ratios of: 1.05 (95% CI 1.02–1.09), p < 0.005, 1.40 (95% CI 
1.22–1.60), p < 0.001, and 0.77 (95% CI 0.63–0.93), p < 0.007, respectively. In a stepwise multiple 
linear regression model, RDW was correlated with hemoglobin concentration (standardized b = –0.233, 
p < 0.001), mean corpuscular volum (standardized b = –0.230, p < 0.001), mean corpuscular hemo-
globin concentration (standardized b = –0.207, p < 0.007), the natural logarithm of C-reactive protein 
(CRP) (standardized b = 0.184, p < 0.004) and tricuspid regurgitation peak gradient (TRPG) values 
(standardized b = 0.179, p < 0.006), whereas MVe’ was correlated with atrial fibrillation (standardized 
b = 0.269, p < 0.001). 
Conclusions: The present data demonstrates a novel relation between higher levels of RDW and elevated 
TRPG and high sensitivity CRP values in patients with AHF. These findings suggest that RDW, the most 
important mortality predictor, is independently associated with elevated pulmonary pressure and systemic 
inflammation in patients with AHF. Moreover, in AHF patients, more advanced age and decreased MVe’ 
are also independently associated with total mortality risk. (Cardiol J XXXX; XX, X: xx–xx)
Key words: acute heart failure, red cell distribution width, anemia, MVe’,  
tricuspid regurgitation peak gradient, high sensitivity C-reactive protein
Introduction
Heart failure (HF) is becoming one of the most 
important cardiovascular syndromes due to its 
increasing prevalence, high mortality and increas-
ing cost of care. Despite progress in therapeutic 
methods for acute heart failure (AHF), it still car-
ries a grim prognosis and that is why searching 
for reliable predictors of mortality is of utmost 
importance [1]. Among them, red cell distribution 
width (RDW) was found to be the cheapest and 
most widely available indicator. The RDW was 
established to be a strong predictor of mortality in 
the general population above 45 years of age [2], 
as well as during sepsis, trauma and in critically ill 
patients [3–5]. Several studies confirmed that RDW 
predicts mortality in acute and chronic heart failure 
(CHF) [5–9]. It was reported that an increasing 
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RDW value is associated with cytokine activation, 
impaired iron mobilization and decreased hemo-
globin (Hb) levels [10–12]. Furthermore, impaired 
deformability of erythrocytes (RBC) caused by 
proinflammatory cytokines can also be manifested 
as increased RDW [4]. The exact mechanism of 
how elevated RDW is associated with an adverse 
prognosis has not been entirely elucidated and 
its relation to clinical findings has not been fully 
explained. Recently, it was documented that high 
RDW values were independently associated with 
increased left ventricular (LV) end diastolic pres-
sure [13]. Data concerning the association of RDW 
with echocardiographic findings in AHF are scarce 
and ambiguous [5, 6, 14]. The aim of the present 
study was to evaluate the mid-term prognostic 
value of RDW in AHF with regards to clinical and 
echocardiographic data. 
Methods 
The retrospective study included 170 patients 
chosen from 237 consecutive patients admitted to 
the hospital due to recent resting dyspnea caused 
by decompensation of CHF. All patients had N-
terminal pro-B-type natriuretic peptide (NT-proB-
NP) plasma levels that were above 300 units and 
signs of systolic and/or diastolic LV dysfunction in 
resting transthoracic echocardiography (ECHO) 
performed within 24 h of admission. The follow-
ing exclusion criteria were applied: age younger 
than 18 years, valvular heart abnormality higher 
than moderate, acute coronary syndrome, dyspnea 
due to concomitant respiratory failure, malignancy 
and incomplete data (Fig. 1). All patients were 
treated according to the current guidelines for 
congestive heart failure (HF). Pharmacotherapy 
on admission was presented in Tables 1 and 2. 
Each patient underwent a standard echocardio-
gram (Vivid 5, GE Vingmed) using an adaptive 
1.3–4.0 MHz transducer. Left atrial diameter 
(LAd), LV end-diastolic diameter (LVEDD) and 
right ventricular end-diastolic diameter (RVEDD) 
were assessed. The tricuspid regurgitation peak 
gradient (TRPG) was calculated according to the 
simplified Bernoulli formula, and was measured 
using a continuous wave Doppler in the modified 
apical 4-chamber view. The transmitral early di-
astolic velocity (E) was assessed from the mitral 
inflow velocity. The LV ejection fraction (LVEF) 
was measured using the Simpson biplane method. 
Tissue Doppler myocardial imaging (TDI) was 
used to assess the peak early diastolic velocity of 
the lateral mitral annulus (MVe’) by placing the 
Doppler sample volume over the lateral side of 
the mitral annulus at the posterior leaflet. Venous 
blood samples were taken for determination of 
serum creatinine, sodium level, high sensitivity 
C-reactive protein (hsCRP), D-dimer, NT-proBNP 
and a complete blood count. Laboratory analysis 
was performed using a COBAS C-6000 Analyzer 
(Roche Diagnostic GmGH, Mannheim, Germany). 
Baseline hematologic analyses were performed 
using SYSMEX XT 1800i. The reference range 
for RDW was 11.5–14.5%. The glomerular filtra-
tion rate (GFR) was calculated according to the 
Modification of Diet in Renal Disease (MDRD) 
formula. Follow-up began on of the day of admis-
sion to the Cardiology Department due to AHF. 
The endpoint of this study was all-cause mortality, 
including in-hospital and post-discharge deaths. 
The study protocol was approved by the Warmia 
Figure 1. The flow chart of case enrolment of our study according to the inclusive and exclusive criteria.
Exclusion criteria:
— Valvular heart abnormality more than moderate (32 patients)
— Patients with acute coronary syndrome (10 patients)
— Respiratory failure (7 patients)
— Malignancy (6 patients)
— Incomplete data (2 patients)
N = 57
Patients admitted to the Department 
of Cardiology between January 2014 
and December 2014
N = 227
Final patients analyzed in the study
N = 170
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Table 1. Baseline characteristics and treatments in patients who died or survived
Variable Survivors (n = 137) Non-survivors (n = 33) P
Age [years] 73.9  ±  12.5 78.3  ±  9.4 0.1
Sex, male 75 (54.7%) 14 (42.42%) 0.2
Diabetes mellitus 44 (32.12%) 16 (48.48%) 0.08
Hypertension 92 (67.15%) 21 (63.64%) 0.7
CAD 20 (14.60%) 9 (27.27%) 0.08
COPD 23 (16.79%) 7 (21.21%) 0.6
History of DVT 9 (6.57%) 6 (18.18%) 0.04
Acute infection 50 (36.5%) 9 (27.27%) 0.3
Heart rate [bpm] 78.42 ± 17.03 85.6 ± 15.89 0.03
BP systolic [mmHg] 136.8 ± 26.5 133.3 ± 21.7 0.5
BP diastolic [mmHg] 80.8 ± 15.2 82.0 ± 14.4 0.7
Weight [kg] 83.1 ± 19.5 77.6 ± 11.8 0.1
BMI [kg/m²] 30.9 ± 6.5 28.3 ± 4.2 0.03
NT-proBNP [pg/mL] 2539 [1431-5496] 4240 [2028-9090] 0.03
Hb [g/dL] 12.8 ± 2.3 11.8 ± 2.7 0.04
RDW [%] 15.0 ± 1.8 16.9 ± 2.9 0.00003
Ht [%] 39.07 ± 6.27 37.03 ± 7.84 0.1
MCV [fL] 90.78 ± 6.88 90.66 ± 9.44 0.9
MCHC [g/dL] 32.87 ± 1.69 32.44 ± 1.46 0.2
Leukocytes [G/mL] 8.3 ± 3.3 7.7 ± 3.2 0.3
PLT [G/mL] 217.8 ± 126.9 186.1 ± 92.3 0.2
Na [mmol/L] 139.2 ± 4.3 137.9 ± 5.1 0.1
Creatinine [mg/dL] 1.2 ± 0.4 1.3 ± 0.6 0.3
eGFR [mL/min/1.73 m2] 62.5 ± 26.5 58.5 ± 23.6 0.4
CRP [mg/L] 3.7 [1.5-12.7] 14.0 [5.0-34.8] 0.0005
D-dimer [μg/mL] 0.9 [0.5-1.5] 1.7 [0.7-3.1] 0.02
LBBB 12 (8.76%) 3 (9.09%) 1.0
RBBB 6 (4.38%) 3 (9.09%) 0.3
AF 68 (49.64%) 16 (48.49%) 0.91
LAd [cm] 4.9 ± 0.8 4.9 ± 0.6 0.8
LVEDD [cm] 5.6 ± 0.9 5.5 ± 1.0 0.9
RVEDD [cm] 3.3 ± 0.7 3.3 ± 0.7 0.9
EF [%] 43.1 ± 15.2 41.6 ± 17.2 0.6
TRPG [mmHg] 35.9 ± 13.6 42.2 ± 14.4 0.02
E [cm/s] 94.9 ± 29.4 84.7 ± 26.6 0.07
MVe’ [cm/s] 8.5 ± 2.6 7.3 ± 1.7 0.01
E/MVe’ 12.4 ± 4.7 12.5 ± 2.7 0.8
Mitral regurgitation 24 (17.52%) 5 (15.15%) 0.8
ACEI/ARB 129 (94.16%) 27 (81.82%) 0.02
Spironolactone 74 (54.01%) 23 (69.70%) 0.1
Furosemide 103 (75.18%) 26 (78.79%) 0.7
Chlortalidone 44 (32.12%) 6 (18.18%) 0.1
Hydrochlorothiazide 24 (17.52%) 5 (15.15%) 0.8
Oral anticoagulant 89 (64.96%) 18 (54.55%) 0.3
Statins 76 (55.47%) 13 (39.39%) 0.1
Beta-blockers 118 (86.13%) 25 (75.76%) 0.1 
Data are shown as mean ± standard deviation/median [IQR]/patients’ number (%); IQR — range from 1st to 3rd quartile; CAD — coronary ar-
tery disease; COPD — chronic obstructive pulmonary disease; DVT — deep vein thrombosis; BP — blood pressure; BMI — body mass index; 
NT-proBNP — N-terminal pro-B-type natriuretic peptide; Hb — hemoglobin; RDW — red blood cell distribution width; Ht — hematocrit; MCV 
— mean corspuscular volume; MCHC — mean corpuscular hemoglobin concentration; PLT — platelet count; eGFR — estimated glomerular 
filtration rate; CRP — C-reactive protein; LBBB — left bundle branch block; RBBB — right bundle branch block; AF — atrial fibrillation; LAd 
— left atrium diameter;  LVEDD — left ventricular end-diastolic diameter; RVEDD — right ventricular end-diastolic diameter; EF — ejection fac-
tion; TRPG — tricuspid regurgitation peak gradient; E — early diastolic mitral inflow velocity; MVe’ — peak early diastolic velocity of the mitral 
annulus lateral portion; ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker
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Table 2. Total mortality in relation to clinical measures.
Variable Univariate Cox proportional  
survival analysis (n = 170)
Multivariate Cox proportional  
survival analysis (n = 170)
HR 95% CI P HR 95% CI P
Age [years] 1.034 1.000 1.070 0.05 1.050 1.015 1.087 0.005
Sex, male 0.658 0.330 1.313 0.2
Diabetes mellitus 1.698 0.858 3.361 0.1
Hypertension 0.834 0.410 1.696 0.6
CAD 2.169 0.895 5.257 0.09
COPD 1.328 0.576 3.062 0.5
History of DVT 2.169 0.895 5.257 0.09
Acute infection 1.420 0.660 3.055 0.4
Heart rate [bmp] 1.022 1.006 1.038 0.007
Systolic BP [mmHg] 0.978 1.007 0.317 1.0
Diastolic BP [mmHg] 1.003 0.980 1.026 0.8
Weight [kg] 0.983 0.964 1.003 0.1
BMI [kg/m2] 0.934 0.882 0.989 0.02
NT-proBNP [pg/mL] 1.629 1.161 2.285 0.005
Hb [g/dL] 0.880 0.771 1.005 0.06
RDW [%] 1.348 1.194 1.522 < 0.001 1.396 1.221 1.596 < 0.001
Ht [%] 0.966 0.919 1.016 0.2
MCV [fL] 0.991 0.947 1.036 0.7
MCHC [g/dL] 0.855 0.700 1.043 0.1
Leukocytes [G/mL] 1.030 0.895 1.185 0.7
PLT [G/mL] 0.997 0.992 1.001 0.2
Na [mmol/L] 0.962 0.894 1.034 0.3
Creatinine [mg/dL] 1.544 0.810 2.945 0.2
eGFR [mL/min/1.73 m2] 0.994 0.980 1.009 0.4
CRP [mg/L] 1.476 1.184 1.841 0.001
D-dimer [μg/mL] 1.195 1.076 1.326 0.001
LBBB 1.074 0.328 3.520 0.9
RBBB 2.346 0.715 7.694 0.2
AF 0.996 0.503 1.971 1.0
LAd [cm] 0.965 0.647 1.439 0.9
LVEDD [cm] 0.987 0.681 1.431 0.9
RVEDD [cm] 0.881 0.532 1.459 0.6
EF [%] 0.993 0.972 1.015 0.5
TRPG [mmHg] 1.023 1.001 1.046 0.04
E [cm/s] 0.985 0.971 0.999 0.03
MVe’ [cm/s] 0.846 0.746 0.958 0.009 0.767 0.632 0.931 0.007
E/MVe’ 1.016 0.941 1.097 0.7
Mitral regurgitation 0.996 0.503 1.971 1.0
ACEI/ARB 0.339 0.140 0.822 0.02
Spironolactone 1.614 0.768 3.395 0.2
Furosemide 1.156 0.502 2.664 0.7
Chlortalidone 0.459 0.189 1.112 0.09
Hydrochlorothiazide 1.013 0.390 2.633 1.0
Oral anticoagulant 0.670 0.338 1.330 0.3
Statins 0.537 0.267 1.079 0.08
Beta-blockers 0.468 0.211 1.040 0.06
HR — hazard ratio; CI — confidential interval. The meaning of other abbreviations are the same as in Table 1. 
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and Masuria Medical Chamber Ethics Committee 
(no. 435/06).
Statistical analysis 
Normally distributed variables were reported 
as mean and standard deviation. Variables that did 
not have a normal distribution were reported as 
median and interquartile range. Depending on the 
type of distribution of the variables, the groups 
were compared using the Student t test or the 
Mann-Whitney test. The c2 test was used to com-
pare qualitative variables between groups. A value 
of p < 0.05 was considered statistically significant.
Variables selected to be tested in multivariate 
analysis were those with p < 0.1 in the univariate 
model. Multivariate survival analysis was per-
formed using the Cox proportion hazard model 
to determine which factors were significantly as-
sociated with death after adjustment for the other 
variables. A stepwise selection was done using a 
p to remove and a p to enter into the model ≤ 0.05 
with both prior backward selection after inclusion 
of all selected variables and then forward selection. 
For the receiver operator characteristic (ROC) 
Youden Index was used to find the optimal cut-off 
points for the best discrimination of death risk. 
Kaplan-Meier survival curves analysis for the 
optimal cut-off point of RDW was created and sta-
tistical comparison between survival curves was 
done using the log-rank test.  
Linear regression analysis was used to evalu-
ate association between clinical variables and the 
most important independent death predictors. 
Identified variables (p < 0.1) were considered to 
enter in a stepwise manner to the multivariate 
linear regression model. The variable retention 
criterion was set at ≤ 0.05.  
All statistical analysis was performed using 
STATSTICA 12 software. 
Results
The study included 170 patients (males 
47.7%). The mean observation time was 193 ± 
111 days. Within the follow-up period, 33 (19.4%) 
patients died. 
The baseline characteristics of the survivor 
and non-survivor groups are presented in Table 1. 
For survivors, the mean age was 73.9 ± 12.5 and 
for non-survivors the mean age was 78.3 ± 9.4 
years (p = 0.1). A history of deep vein thrombo-
sis was more frequent in the non-survivors group 
(18.2% vs. 6.6%, p < 0.04). There was a similar 
prevalence of reported comorbidities and acute 
infections in both studied groups. The number of 
subjects with anemia in survivors and non-survi-
vors in the study group was 56 (40.88%) and 19 
(57.58%), respectively (p = 0.08). After exclusion 
of anemic subjects, the median value of RDW in 
survivors and non-survivors was 14.4 (13.8–15.5) 
and 15.7 (14.6–17.30), respectively (p = 0.03). 
Treatment with angiotensin-converting enzyme 
inhibitor/angiotensin receptor blocker (ACEI/ARB) 
was significantly more frequent in the survivors 
group. Biochemical and clinical analyses revealed 
significantly higher concentration of NT-proBNP, 
CRP, D-dimer, and higher RDW and TRPG values 
in non-survivors (Table 1). In the non-survivors 
group, significantly lower Hb concentration and 
diminished MVe’ values were found.  
The univariate relative risk of mortality in re-
lation to clinical variables is listed in Table 2. The 
presence of advanced age, higher values of NT-pro-
BNP, CRP, D-dimer, RDW, TRPG, and lower values 
of mitral E and MVe’ were related to total mortality.
The multivariate relative risk of mortality in 
relation to clinical variables is presented in Table 2. 
Advanced age, increased RDW value and decreased 
lateral MVe’ velocity were retained as independ-
ent predictors for all-cause mortality with hazard 
ratios of 1.05 (95% CI 1.02–1.09), p < 0.005, 1.40 
(95% CI 1.22–1.60), p < 0.001, and 0.77 (95% CI 
0.63–0.93), p < 0.007, respectively.
In the univariate linear regression analysis, 
RDW was positively correlated with the natural 
logarithm of CRP (LnCRP), TRPG, NT-proBNP and 
RVEDD. Negative RDW correlation was found with 
Hb, hematocrit, mean corpuscular volume (MCV) 
and mean corpuscular hemoglobin concentration 
(MCHC) values. In the stepwise multiple linear 
regression model, RDW was correlated with Hb, 
MCV, MCHC, LnCRP and TRPG values (Table 3).
In the stepwise multiple linear regression 
model, MVe’ was correlated with the presence 
of atrial fibrillation (AF) (standardized b = 0.269, 
p < 0.001).
In the whole study group the ROC curve 
analysis for RDW revealed that area under curve 
(AUC) was 0.72 (95% CI 0.62–0.82; p < 0.0001). 
The ROC curve analysis in the subgroup without 
anemia revealed AUC of 0.69 (95% CI 0.53–0.84; 
p < 0.02). RDW value ≥ 14.6 was found to be the 
optimal cut-off point for the discrimination of death 
risk. The same value of optimal cut-off point was 
found for non-anemic patients. RDW value ≥ 14.6 in 
the whole study group was found to have sensitivity 
and specificity of 86% and 51% and for non-anemic 
patients 78.6% and 56.0%, respectively. 
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Table 3. Univariate and multivariate analysis of association of patient characteristics with RDW
Variable Univariate linear regression analysis Multivariate linear regression analysis
b unstandarised ± SD b standarised P b unstandarised ± SD b standarised P
Age [years] –0.014 ± 0.014 –0.078 0.3      
Sex, male 0.175 ± 0.168 0.080 0.3      
Diabetes mellitus 0.140 ± 0.175 0.062 0.4      
Hypertension –0.289 ± 0.175 –0.126 0.1      
CAD 0.275 ± 0.224 0.095 0.2      
COPD –0.348 ± 0.217 –0.123 0.1      
DVT history 0.001 ± 0.265 0 1.0      
Acute infection –0.064 ± 0.177 –0.028 0.7      
Heart rate [bpm] 0.018 ± 0.010 0.143 0.06
Systolic BP [mmHg] –0.0003 ± 0.007 –0.003 1.0
Diastolic BP [mmHg] –0.006 ± 0.011 –0.038 0.6
Weight [kg] –0.002 ± 0.009 –0.016 0.8
BMI [kg/m2] –0.028 ± 0.027 –0.079 0.3
NT-proBNP [pg/mL] 0.000 ± 0.000 0.181 0.02
Hb [g/dL] –0.356 ± 0.065 –0.392 < 0.001 –0.212 ± 0.065 –0.233 0.001
Ht [%] –0.108 ± 0.024 –0.331 < 0.001    
MCV [fL] –0.108 ± 0.021 –0.369 < 0.001 –0.067 ± 0.02 –0.23 0.001
MCHC [g/dL] –0.557 ± 0.092 –0.425 < 0.001 –0.271 ± 0.099 –0.207 0.007
Leukocytes [G/mL] –0.042 ± 0.051 –0.064 0.4      
PLT [G/mL] 0.002 ± 0.001 0.094 0.2      
Na [mmol/L] –0.053 ± 0.037 –0.109 0.2      
Creatinine [mg/dL] 0.572 ± 0.347 0.127 0.1      
eGFR [mL/min/1.73 m2] 0.004 ± 0.006 0.051 0.5
LnCRP [mg/L] 0.330 ± 0.109 0.229 0.003 0.266 ± 0.092 0.184 0.004
D-dimer [μg/mL] 0.160 ± 0.085 0.143 0.06      
LBBB –0.267 ± 0.297 –0.069 0.4      
RBBB 0.603 ± 0.374 0.123 0.1
AF 0.142 ± 0.169 0.065 0.4
LAd [cm] 0.335 ± 0.209 0.123 0.1
LVEDD [cm] 0.167 ± 0.179 0.072 0.4
RVEDD [cm] 0.523 ± 0.238 0.168 0.03
EF [%] –0.010 ± 0.011 –0.073 0.3
TRPG [mmHg] 0.035 ± 0.012 0.227 0.003 0.028 ± 0.01 0.179 0.006
E [cm/s] 0.004 ± 0.006 0.057 0.5
MVe’ [cm/s] 0.003 ± 0.003 0.078 0.3
E/MVe’ 0.051 ± 0.039 0.101 0.2
Mitral regurgitation 0.286 ± 0.223 0.098 0.2
SD — standard deviation; the meaning of all abbreviations are the same as in Table 1 and Table 2.
When Kaplan-Meier survival curves for 1-year 
mortality were constructed, patients with RDW 
≥ 14.6 had a 1-year cumulative survival proba-
bility of 65% compared with 92% for those with 
RDW < 14.6 (p < 0.001 in log-rank test) (Fig. 2). 
Number of patients at risk in the group assessed 
with RDW ≥ 14.6 was 97 and in the group with 
RDW < 14.6 was 73 subjects.
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Discussion
Elevated RDW on admission is the most pow-
erful independent predictor of all-cause mortality 
in AHF patients. A 1% RDW increase predicted an 
almost 40% increase in total mortality risk, which 
is consistent with previously reported data in AHF 
[6, 7, 15–17]. 
There are numerous reasons for RDW eleva-
tion under different clinical conditions. Tradition-
ally, an isolated rise in RDW is the first abnor-
mality seen in early iron deficiency and coupled 
with a low MCV is regarded as being diagnostic 
of absolute iron deficiency [16, 17]. Hemoglobin 
concentration and automatically measured red 
cell indices are considered sensitive indicators of 
systemic iron status [18]. It was found that iron 
deficiency is an ominous finding in CHF [17]. As 
the deficit worsens, the MCHC falls with a further 
reduction in MCV. In the present study, increased 
RDW was independently correlated with a low 
Hb level, as well as decreased MCV and MCHC 
values. Similar correlations have been described 
by other authors [8, 19] in AHF patients. In a re-
cent study by Senthong et al. [13] this correlation 
was observed in patients who underwent elective 
coronary angiography. Moreover, van Kimmenade 
et al. [8] found no correlation between increased 
RDW and serum iron, TIBC, serum transferin 
saturation and ferritin level. Allen et al. [10] dem-
onstrated similar findings in CHF patients. They 
additionally found a correlation between elevated 
RDW and high eyrthropoetin levels, normal iron 
binding capacity and ferritin levels. All results are 
consistent with a state of impaired iron mobiliza-
tion and the inhibition of erythropoietin-induced 
erythrocyte maturation, the hallmark of anemia 
in chronic diseases [20]. There is an increasing 
recognition that in the AHF population, the ability 
to mobilize and use existing iron stores may be 
impaired even in the setting of adequate overall 
total body iron [21]. This is sometimes referred to 
as “reticuloendothelial block”, and it is mediated in 
part by the overexpression of hepcidin; a peptide 
hormone secreted by the liver which is upregulated 
by inflammation and acts as a regulator of human 
iron metabolism [10, 22].
In the entire study group, an association be-
tween lower MCV, MCHC and Hb concentration 
with higher RDW may indicate an underlying iron 
deficiency, but it cannot be excluded that the RDW 
value is also modified by erythrocyte destruction 
and ineffective iron utilization for red cell produc-
tion [23]. In rodent models of sepsis, decreases in 
Hb content and erythrocyte deformability resulting 
in RDW elevation was shown to be most profound 
in the second-oldest subpopulation of cells ac-
counting for 20% of total circulating erythrocytes 
[24]. On the other hand, it was demonstrated that 
RDW elevation is caused by a rise of immature 
erythrocyte forms [11].
In the present study group, increased RDW 
was independently positively correlated with hs-
CRP level. Lippi et al. [23] demonstrated a similar 
correlation in an unselected population between 
high RDW and elevated CRP concentration. It was 
reported that inflammation alters erythropoiesis 
by direct myelosuppression of erythroid precur-
sors, promotion of red cell apoptosis, reduction of 
erythropoietin production, reduced iron bioavail-
ability, and erythropoietin resistance in erythroid 
precursor cell lines. CRP contributes to stimulating 
the secretion of cytokines and tissue factor, it also 
induces the expression of adhesion molecules from 
endothelial cells [25]. Inflammatory cytokines also 
suppress erythrocyte maturation, allowing newer, 
larger reticulocytes to enter the circulation and 
skew the RDW distribution [4]. An inverse cor-
relation between RDW and MCV, MCHC and Hb 
values indicate that proliferation and new erythro-
cytes entering into circulation are less important 
than erythrocyte destruction in the study group. 
The median hsCRP value in the non-survivors 
group was 14.0 (5.0–34.8) mg/L. The elevation 
of hsCRP above 10 mg/L should be evaluated for 
noncardiovascular etiologies, most likely resulting 
from an infection [26]. The prevalence of acute 
Figure 2. Kaplan-Meier survival curves for total mortal-
ity in 170 patients with acute heart failure with red cell 
distribution width (RDW) ≥ 14.6 (n = 97) and RDW 
< 14.6 (n = 73).
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infection was similar for both the survivors and 
non-survivors group. Therefore, it seems that in 
AHF patients studied, destruction of erythrocytes 
is associated not only with HF related vascular 
inflammation but probably also with severity of the 
superimposed infection. 
The inflammatory process, particularly ac-
companying HF, is an important pro-thrombotic 
factor. In the present study, D-dimer concentration 
was significantly higher in the non-survivors group 
in univariate regression analysis and a significant 
positive correlation between D-dimer and RDW 
was observed. No patients had clinical symptoms 
of recent deep vein thrombosis or acute coronary 
syndrome, so activated fibrinolysis is rather con-
nected with other vascular territories. Itani et al. 
[7] found that a higher DIC score was independent-
ly associated with risk of death in AHF patients. 
Interestingly, it was reported that in patients with 
hypoxemia and pulmonary hypertension due to HF, 
endothelial dysfunction and ongoing intravascular 
coagulation was associated with the occurrence 
of ischaemic and thrombotic pulmonary events 
[27]. In a mixed etiology pulmonary hypertension 
population, it was demonstrated that elevated RDW 
levels were inversely correlated with Hb and MCV 
values which is in line with the present results [12]. 
Tandon et al. [28] described extensive thrombotic 
pulmonary vascular changes at various stages of 
organization with pulmonary iron deposits seen in 
70% of cases in patients with severe pulmonary hy-
pertension due to isolated mitral stenosis. Similar 
abnormalities were described in HF and pulmonary 
hypertension [29]. 
According to available research, the current 
study provides the first data evaluating the relation-
ship between the RDW and TRPG values in AHF. 
An independent direct positive correlation between 
RDW with TRPG values in the present study group 
may indicate the role of elevated pulmonary artery 
pressure on the modification of RDW values. It has 
been proven that blood stasis, due to low cardiac 
output, passive vascular distension, and systemic 
inflammation leads to endothelial dysfunction by 
means of neurohormonal activation [30]. Costello 
et al. [31] have described disruption of some or 
all layers of the alveolar-capillary unit by elevated 
capillary hydrostatic pressures, a phenomenon they 
referred to as pulmonary capillary stress failure. 
When all of the layers are disrupted, RBCs may be 
seen traversing the alveolarcapillary membrane. 
It was found that RBC destruction releases free 
Hb, and these react with nitric oxide to form inac-
tive nitrate and methemoglobin, thus leading to 
endothelial dysfunction [32]. Recently in a murine 
model of hemolysis, a significant reduction in nitric 
oxide bioavailability due to free Hb was shown 
to be accompanied by platelet activation and the 
activation of a coagulation pathway resulting in 
thrombosis, pulmonary hypertension, right ven-
tricular failure and eventually death [32]. The im-
pact of increased pulmonary pressure on vascular 
endothelial cells in AHF may lead to erythrocyte 
damage and serve as an important modifier of the 
RDW. Free Hb leads to further microcirculation 
damage and creation of a self-perpetuating vicious 
circle. It has been demonstrated that unfraction-
ated heparin treatment in cardio-renal syndrome 
and peripheral vein thrombosis without pulmonary 
embolism resulted in lowering pulmonary arterial 
hypertension and increased plasma anticoagulants 
indicating the thrombotic nature of the underlying 
pathology which plays an important role in pulmo-
nary circulation of AHF patients [33]. 
Results herein demonstrate that decreased 
MVe’, unlike LVEF and other echocardiographic 
data including the E/MVe’ ratio in AHF patients, 
independently predicts risk of death. Gandhi et al. 
[34] first described that the impairment of diastolic 
dysfunction in patients with sinus rhythm is as-
sociated with the development of acute pulmonary 
edema with normal and unchanged LVEF. The MVe’ 
value is a key indicator of diastolic function because 
it reflects both relaxation and restoration forces 
[35]. It is commonly assumed that in the failing 
heart, MVe’ is modified by diastolic pressure but is 
less load dependent than transmitral flow velocities 
[35]. However, AF changes the ventricular diastolic 
filling profile from double to single phase, leading 
to a significant increase of maximal MVe’ velocity, 
falsely denotes a better LV diastolic function. The 
prevalence of AF in the survival and nonsurvival 
groups was similar; therefore, AF is not likely to 
be a factor affecting MVe’ predictability of death in 
the present study group. It was demonstrated that 
early diastolic mitral annulus velocity in patients 
with LV systolic dysfunction and sinus rhythm was 
found to be a powerful predictor of cardiac mortality. 
Moreover, MVe’ emerged as the best prognosticator 
for long-term follow-up and was even more accurate 
than the E/e’ ratio, incremental to other clinical or 
echocardiographic variables in patients with im-
paired LV systolic function [36]. It was also reported 
that the presence of diastolic dysfunction provides 
important prognostic insights in patients with HF, 
especially preserved ejection fraction and sinus 
rhythm [36, 37]. According to available research, 
there is no published data concerning the prog-
8 www.cardiologyjournal.org
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nostic impact of MVe’ in AHF groups consisting of 
patients with preserved as well as reduced ejection 
fraction. However, further analysis of a larger mixed 
HF population with and without AF are needed to 
establish absolute predictive values separately for 
patients with AF and those with sinus rhythm.
Limitations of the study
The present study has several limitations. 
Firstly, the study was performed at a single 
center with a small, retrospective sample size, 
which raises a concern of whether the sample is 
representative. However, demographic, clinical, 
and biological characteristics of the present study 
collectively correspond with the respective char-
acteristics reported from other studies of AHF 
[6, 19].
Secondly, analysis of precise indices of iron 
metabolism, transfusion status or nutritional defi-
ciency was not carried out.
Thirdly, analysis of TRPG was performed 
instead of a direct invasive pulmonary pressure 
estimation.
Conclusions
The present data demonstrates a novel re-
lation between higher levels of RDW, elevated 
TRPG and elevated hsCRP values in patients with 
AHF. These findings suggest that RDW, the most 
important mortality predictor, is independently 
associated with elevated pulmonary pressure 
and systemic inflammation in patients with AHF. 
Moreover, more advanced age and a decreased 
MVe’ are also independently associated with total 
mortality risk in AHF patients. 
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